亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion

医学 尿激酶 安慰剂 胸膜成形术 随机对照试验 恶性胸腔积液 危险系数 外科 胸腔积液 置信区间 胸膜疾病 麻醉 内科学 呼吸道疾病 肺 替代医学 病理
作者
Eleanor K. Mishra,Amelia O. Clive,Genevieve H. Wills,Helen E. Davies,Andrew Ewing Stanton,M. Al-Aloul,Alan Hart-Thomas,Justin Pepperell,Matthew Evison,Tarek Saba,Richard Neil Harrison,Anur Guhan,Matthew E.J. Callister,Ramamurthy Sathyamurthy,Sunita Rehal,John P. Corcoran,Rob Hallifax,Ioannis Psallidas,Nicky Russell,Rachel Shaw
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:197 (4): 502-508 被引量:78
标识
DOI:10.1164/rccm.201704-0809oc
摘要

RATIONALE: Patients with malignant pleural effusion experience breathlessness, which is treated by drainage and pleurodesis. Incomplete drainage results in residual dyspnea and pleurodesis failure. Intrapleural fibrinolytics lyse septations within pleural fluid, improving drainage. OBJECTIVES: To assess the effects of intrapleural urokinase on dyspnea and pleurodesis success in patients with nondraining malignant effusion. METHODS: We conducted a prospective, double-blind, randomized trial. Patients with nondraining effusion were randomly allocated in a 1:1 ratio to intrapleural urokinase (100,000 IU, three doses, 12-hourly) or matched placebo. MEASUREMENTS AND MAIN RESULTS: Co-primary outcome measures were dyspnea (average daily 100-mm visual analog scale scores over 28 d) and time to pleurodesis failure to 12 months. Secondary outcomes were survival, hospital length of stay, and radiographic change. A total of 71 subjects were randomized (36 received urokinase, 35 placebo) from 12 U.K. centers. The baseline characteristics were similar between the groups. There was no difference in mean dyspnea between groups (mean difference, 3.8 mm; 95% confidence interval [CI], -12 to 4.4 mm; P = 0.36). Pleurodesis failure rates were similar (urokinase, 13 of 35 [37%]; placebo, 11 of 34 [32%]; adjusted hazard ratio, 1.2; P = 0.65). Urokinase was associated with decreased effusion size visualized by chest radiography (adjusted relative improvement, -19%; 95% CI, -28 to -11%; P < 0.001), reduced hospital stay (1.6 d; 95% CI, 1.0 to 2.6; P = 0.049), and improved survival (69 vs. 48 d; P = 0.026). CONCLUSIONS: Use of intrapleural urokinase does not reduce dyspnea or improve pleurodesis success compared with placebo and cannot be recommended as an adjunct to pleurodesis. Other palliative treatments should be used. Improvements in hospital stay, radiographic appearance, and survival associated with urokinase require further evaluation. Clinical trial registered with ISRCTN (12852177) and EudraCT (2008-000586-26).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
madeleinli的应助被纯情的阁采纳,获得10
18秒前
慕青的应助被纯情的阁采纳,获得10
18秒前
madeleinli的应助被纯情的阁采纳,获得10
19秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
19秒前
19秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
19秒前
小蘑菇的应助被纯情的阁采纳,获得10
19秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
20秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
20秒前
20秒前
单纯冰菱完成签到,获得积分10
22秒前
29秒前
火星上的山柳完成签到,获得积分10
31秒前
34秒前
大个的应助被Eva小飞鱼采纳,获得10
49秒前
称心的忆山完成签到,获得积分10
52秒前
1分钟前
agathahqs的应助被纯情的阁采纳,获得30
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
null的应助被纯情的阁采纳,获得10
1分钟前
null的应助被纯情的阁采纳,获得10
1分钟前
奔跑的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
冷傲的中恶完成签到,获得积分10
1分钟前
敏感兰完成签到,获得积分10
1分钟前
double_sweet完成签到,获得积分10
1分钟前
Benhnhk21完成签到,获得积分10
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
顾矜的应助被纯情的阁采纳,获得10
1分钟前
完美的飞兰完成签到,获得积分10
1分钟前
1分钟前
纯情的阁发布了新的文献求助10
2分钟前
暴躁的尔柳完成签到,获得积分10
2分钟前
2分钟前
阔达之卉完成签到 ,获得积分10
2分钟前
欢喜的小蕾完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158827
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552000
邀请新用户注册赠送积分活动 2471370